Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Am J Kidney Dis. 2020 May 16;76(6):775–783. doi: 10.1053/j.ajkd.2020.03.015

Table 1:

Characteristics of the study population at baseline visit 4 (1996–1998) and baseline visit 5 (2011–2013), the Atherosclerosis Risk in Communities (ARIC) Study cohort.

Visit 4 (1996–1998)
N = 9967
Visit 5 (2011–2013)
N = 4626

Age, years, mean (SD) 62.8 (5.7) 75.5 (5.2)
Female 5701 (57.2) 2637 (57.0)
African-American 2029 (20.4) 1003 (21.7)
Education
 <High school 1850 (18.6) 599 (12.9)
 High school or GED 4243 (42.6) 1908 (41.2)
 >High school 3874 (38.9) 2119 (45.8)
Smoking
 Current 1413 (14.2) 256 (5.7)
 Former 4312 (43.5) 2165 (47.9)
 Never 4195 (42.3) 1708 (37.8)
Apolipoprotein E4 status
 TT = 0 Alleles 6743 (69.9) 3236 (72.2)
 CT = 1 Allele 2651 (27.5) 1167 (26.1)
 CC = 2 Alleles 247 (2.6) 80 (1.8)
Body mass index (BMI), kg/m2
 Underweight (<18.5) 73 (0.7) 45 (1.0)
 Normal weight (18.5 – 25) 2523 (25.3) 1091 (23.5)
 Overweight (25 – 30) 3934 (39.5) 1793 (38.8)
 Obese (>30) 3437 (34.5) 1697 (36.7)
Diabetes 1543 (15.5) 1459 (32.3)
Systolic blood pressure, mmHg, mean (SD) 133.9 (21.2) 130.5 (18.1)
Antihypertensive medication 4165 (41.8) 3470 (75.1)
C-reactive protein (CRP), mg/l, median (IQR) 2.4 (1.1, 5.4) 2.0 (1.0 – 4.2)

Measures of kidney function

Estimated Glomerular Filtration Rate (eGFR),
ml/min per 1.73m2, median (IQR)
 CKD-EPI, Creatinine 89.2 (76.7, 96.2) 70.9 (58.2, 83.0)
 CKD-EPI, Cystatin-C 85.2 (73.0, 97.3) 60.9 (47.9, 74.7)
   CKD-EPI, Creatinine + Cystatin-C 87.3 (76.6, 97.1) 66.1 (53.8, 78.3)
 CKD-EPI, Beta-2-Microglobulin 75.3 (66.4, 84.6) 64.0 (54.0, 73.4)
Urine albumin-to-creatinine ratio (UACR),
mg/g Creatinine, median (IQR)
3.7 (1.8, 7.5) 10.3 (6.3, 21.7)

Data are presented as number (%) unless otherwise specified.